Halyard Health (HYH) Tops Q2 EPS by 9c

Halyard Health (NYSE: HYH) reported Q2 EPS of $0.45, $0.09 better than the analyst estimate of $0.36. Revenue for the quarter came in at $400 million versus the consensus estimate of $383.08 million.

2016 Outlook and Key Planning Assumptions

The company is revising its previously announced full-year 2016 outlook.

• Adjusted diluted earnings per share are expected to be in the range of $1.70 to $1.90.

Based on current trends, the company is updating some of its key planning assumptions, as described below.

• Total net sales, on a constant currency basis including Corporate sales of $5 to $15 million but excluding CORPAK, are expected to range from a decline of 2 to 4 percent compared to 2015.
• S&IP net sales, on a constant currency basis and excluding net sales to Kimberly-Clark, are expected to range from a decline of 2 to 4 percent compared to 2015.
• The foreign currency translation impact to net sales is expected to be even compared to the prior year.
• Inflation in key inputs is expected to be unchanged compared to the prior year.

For earnings history and earnings-related data on Halyard Health (HYH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c